ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,023.90
      -0.23%
      US Tech 100
      16,867.20
      -0.69%
      Dow Jones
      37,927.81
      0.30%
      Brent Oil
      83.795
      -2.44%
      Bitcoin
      56,959.18
      -6.00%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. NGM Biopharmaceuticals Inc (NGM)

      7. NGM Biopharmaceuticals Inc (NGM) News

      NGM

      NGM Biopharmaceuticals (NGM)

      NGM Biopharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:NGM
      DateTimeSourceHeadlineSymbolCompany
      04/05/20249:19AMGlobeNewswire Inc.NGM Bio Announces Closing of Tender OfferNASDAQ:NGMNGM Biopharmaceuticals Inc
      03/19/20245:30PMGlobeNewswire Inc.NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
      03/11/20244:15PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NGMNGM Biopharmaceuticals Inc
      03/11/20244:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      03/11/20244:05PMGlobeNewswire Inc.NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
      03/08/20245:32PMEdgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:NGMNGM Biopharmaceuticals Inc
      03/08/20245:21PMEdgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:NGMNGM Biopharmaceuticals Inc
      02/26/20245:11PMEdgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:NGMNGM Biopharmaceuticals Inc
      02/26/20245:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      02/26/20249:03AMGlobeNewswire Inc.NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPNASDAQ:NGMNGM Biopharmaceuticals Inc
      02/20/20244:01PMGlobeNewswire Inc.NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
      02/14/20246:12PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
      01/22/20246:09AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/18/20246:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/18/20246:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/18/20246:01PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/17/20244:47PMGlobeNewswire Inc.NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/09/20248:00AMGlobeNewswire Inc.NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedNASDAQ:NGMNGM Biopharmaceuticals Inc
      01/02/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      12/04/20235:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      12/04/20234:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/13/20239:45AMGlobeNewswire Inc.NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/08/20236:13PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/08/20236:11PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/08/20236:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/08/20236:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/07/20234:05PMGlobeNewswire Inc.NGM Bio to Participate in Upcoming Investor ConferencesNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/02/20234:12PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NGMNGM Biopharmaceuticals Inc
      11/02/20234:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
      11/02/20234:01PMGlobeNewswire Inc.NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:NGM